Rebecca S Chinthrajeh, MD
Allergy/Immunology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chinthrajeh’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A94106 · Current
Licensed to practise in California · since 2006 · expires 2027-12-31 · Drexel University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,160
Medicare paid this office $3,160 for 20 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
20 Original Medicare patients in 2024. Average age 74 · Health risk score 1.51. Sicker patients than 9 in 10 peers; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 75%.
The office billed $13,912, Medicare allowed $4,094 and paid $3,160; for 31 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 20 | 31 | 74 | 1.51 | $13,912 | $3,160 |
| 2023 | 34 | 50 | 73 | 2.35 | $21,391 | $5,292 |
| 2022 | 46 | 58 | 76 | 2.68 | $26,976 | $6,166 |
| 2021 | 56 | 69 | 77 | 1.85 | $28,331 | $7,061 |
| 2020 | 66 | 94 | 72 | 2.36 | $27,716 | $7,336 |
| 2019 | 148 | 257 | 71 | 2.17 | $39,649 | $11,582 |
| 2018 | 72 | 94 | 72 | 1.74 | $10,020 | $7,355 |
| 2017 | 117 | 217 | 71 | 2.03 | $30,169 | $7,957 |
| 2016 | 97 | 160 | 71 | 2.09 | $28,180 | $7,427 |
| 2015 | 102 | 183 | 72 | 2.25 | $27,829 | $6,996 |
| 2014 | 20 | 25 | 73 | 1.40 | $6,467 | $2,216 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,919 | $160 |
2022: 2 services
| Long return visit (40+ min) | 13 | $1,654 | $118 |
| Return visit (30+ min) | 13 | $990 | $76 |
2021: 2 services
| Return visit (30+ min) | 21 | $2,102 | $100 |
| Long return visit (40+ min) | 12 | $1,700 | $131 |
2020: 1 service
| Return visit (30+ min) | 36 | $2,841 | $68 |
2019: 7 services
| Return visit (30+ min) | 27 | $2,512 | $70 |
| New patient visit (45+ min) | 14 | $1,633 | $117 |
| Short return visit (20+ min) | 11 | $604 | $40 |
| Test to measure expiratory airflow and volume | 49 | $378 | $8 |
| Test to examine how well the lungs exchange gases | 44 | $367 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $288 | $12 |
| Test to determine lung volumes using sensors | 16 | $181 | $11 |
2018: 4 services
| Return visit (30+ min) | 28 | $2,472 | $71 |
| Long return visit (40+ min) | 16 | $1,696 | $100 |
| New patient visit (45+ min) | 11 | $1,268 | $115 |
| Short return visit (20+ min) | 11 | $645 | $43 |
2017: 6 services
| Return visit (30+ min) | 21 | $1,711 | $68 |
| Test to examine how well the lungs exchange gases | 48 | $390 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | $286 | $11 |
| Test to measure expiratory airflow and volume | 30 | $221 | $7 |
| Test to determine lung volumes using sensors | 18 | $194 | $11 |
| Test to measure expiratory airflow and volume | 13 | $96 | $7 |
2016: 7 services
| New patient visit (60+ min) | 15 | $2,071 | $138 |
| Return visit (30+ min) | 16 | $1,304 | $69 |
| New patient visit (45+ min) | 11 | $1,243 | $113 |
| Test to examine how well the lungs exchange gases | 35 | $281 | $8 |
| Test to measure expiratory airflow and volume | 25 | $186 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $150 | $12 |
| Test to determine lung volumes using sensors | 11 | $120 | $11 |
2015: 6 services
| New patient visit (60+ min) | 11 | $1,648 | $150 |
| Return visit (30+ min) | 20 | $1,345 | $58 |
| Test to examine how well the lungs exchange gases | 42 | $327 | $8 |
| Test to measure expiratory airflow and volume | 39 | $280 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $176 | $10 |
| Test to determine lung volumes using sensors | 13 | $144 | $11 |
Drugs they prescribed that Part D paid
$9,574
Pharmacies billed $9,574 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 46) in 2024. Too few prescriptions to compare fairly with other clinicians.
19 generic and 27 brand-name prescriptions · $9,574 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Montelukast | 17 | $131 | $8 |
Year by year
| 2024 | 46 | None | 0% (0) | 59% | $9,574 |
| 2023 | 41 | None | 0% (0) | 68% | $11,234 |
| 2022 | 66 | 13 | 0% (0) | 56% | $20,162 |
| 2021 | 71 | 15 | 0% (0) | 61% | $26,089 |
| 2020 | 91 | 19 | 0% (0) | 69% | $32,511 |
| 2019 | 111 | 35 | 0% (0) | 68% | $41,629 |
| 2018 | 201 | 47 | 0% (0) | 66% | $62,338 |
| 2017 | 87 | 33 | 0% (0) | 63% | $18,944 |
| 2016 | 105 | 31 | 0% (0) | 70% | $23,638 |
| 2015 | 113 | 20 | 0% (0) | 54% | $19,031 |
| 2014 | 49 | 17 | 0% (0) | 63% | $8,677 |
| 2013 | 115 | 11 | 0% (0) | 49% | $12,137 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 2 drugs
| Albuterol Sulfate Hfa | 18 | $628 | $35 |
| Montelukast | 13 | $33 | $3 |
2021: 2 drugs
| Albuterol Sulfate Hfa | 12 | $810 | $67 |
| Montelukast | 12 | $42 | $4 |
2020: 2 drugs
| Symbicort | 11 | $6,832 | $621 |
| Montelukast | 13 | $40 | $3 |
2019: 3 drugs
| Symbicort | 20 | $8,418 | $421 |
| Breo Ellipta | 12 | $6,772 | $564 |
| Montelukast | 15 | $133 | $9 |
2018: 9 drugs
| Advair Diskus | 16 | $10,523 | $658 |
| Flovent Hfa | 18 | $8,431 | $468 |
| Spiriva | 14 | $7,279 | $520 |
| Breo Ellipta | 14 | $5,620 | $401 |
| Symbicort | 12 | $4,169 | $347 |
| Proair Hfa | 15 | $1,061 | $71 |
| Ventolin Hfa | 12 | $939 | $78 |
| Azithromycin | 11 | $510 | $46 |
| Prednisone | 18 | $209 | $12 |
2017: 1 drug
| Symbicort | 12 | $4,108 | $342 |
2016: 3 drugs
| Spiriva | 24 | $8,680 | $362 |
| Advair Diskus | 19 | $7,347 | $387 |
| Ventolin Hfa | 11 | $573 | $52 |
2015: 6 drugs
| Spiriva | 16 | $6,559 | $410 |
| Symbicort | 14 | $3,597 | $257 |
| Rifampin | 13 | $1,759 | $135 |
| Proair Hfa | 13 | $845 | $65 |
| Ethambutol | 12 | $829 | $69 |
| Azithromycin | 19 | $610 | $32 |
2013: 4 drugs
| Flovent Hfa | 15 | $3,301 | $220 |
| Proair Hfa | 23 | $1,081 | $47 |
| Montelukast | 23 | $639 | $28 |
| Ipratropium | 13 | $331 | $25 |
Money from drug and device companies
$4,800 in 2025
| 2025 | 1 | 1 | $4,800 | $4,800 |
| 2024 | 3 | 6 | $6,867 | $7,940 |
| 2023 | 2 | 4 | $8,956 | $9,300 |
| 2022 | 3 | 3 | $3,468 | $3,492 |
| 2021 | 2 | 5 | $7,660 | $7,660 |
| 2020 | 4 | 12 | $17,788 | $19,679 |
| 2019 | 3 | 3 | None | $375 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | Xolair | $4,800 | 1 payment
|
See the published payment
| Genentech | Consulting · 2025-02-05 | Xolair | $4,800 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,940
| Genentech | Xolair | $4,950 | 2 payments
|
| Blueprint Medicines | None | $2,067 | 1 payment
|
| Novartis Pharmaceuticals | None | $923 | 3 payments
|
2023: $9,300
| Genentech | Xolair | $4,843 | 3 payments
|
| Novartis Pharmaceuticals | Xolair | $4,456 | 1 payment
|
2022: $3,492
| Aimmune Therapeutics | None | $2,013 | 1 payment
|
| Regeneron Pharmaceuticals | Dupixent | $1,455 | 1 payment
|
| Genentech | Xolair | $25 | 1 payment
|
2021: $7,660
| Novartis Pharmaceuticals | Xolair | $5,995 | 3 payments
|
| Genentech | None | $1,665 | 2 payments
|
2020: $19,679
| Genentech | Xolair | $7,641 | 7 payments
|
| Novartis Pharma AG | Ige025a Xolair Respiratory | $5,995 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $4,360 | 2 payments
|
| Genzyme | Dupixent | $1,683 | 1 payment
|
2019: $375
| Novartis Pharmaceuticals | Xolair | $125 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $125 | 1 payment
|
| Pfizer | Vyndaqel | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy To Evaluate the Efficacy and Safety of Dupilumab As Adjunct To Ar101 (Peanut Oral Immunotherapy) · 2020 | Their institution | $555,440 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy To Evaluate the Efficacy and Safety of Dupilumab As Adjunct To Ar101 Peanut Oral Immunotherapy · 2019 | Their institution | $429,744 |
| Regeneron Pharmaceuticals, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy To Evaluate the Efficacy and Safety of Dupilumab As Adjunct To Ar101 (Peanut Oral Immunotherapy) · 2021 | Their institution | $381,455 |
| Novartis Pharmaceuticals Corporation · A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study To Assess the Efficacy and Safety of Qaw039 When Added To Standard-of-Care Asthma Therapy in Patients With Uncontrolled Asthma · 2019 | Their institution | $36,242 |
| F. Hoffmann-La Roche AG · Safety Profile of Xolair in the Post Marketing Setting A Subanalysis of the Prospero Study · 2024 | This clinician | $4,641 |
| F. Hoffmann-La Roche AG · Effect of Omalizumab on Asthma Outcomes in Adolescents/Adults With Asthma and Food Allergy · 2023 | This clinician | $3,296 |
| F. Hoffmann-La Roche AG · Impact of Food Allergy on Work Productivity and Healthcare Resource Use in Patients With Allergic Asthma Treated With Omalizumab · 2024 | This clinician | $2,768 |
| Novartis Pharmaceuticals Corporation · A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study To Assess the Efficacy and Safety of Qaw039 When Added To Standard-of-Care Asthma Therapy in Patients With Uncontrolled Asthma · 2020 | Their institution | $2,678 |
| F. Hoffmann-La Roche AG · Effect of Omalizumab on Asthma Outcomes in Pediatric Patients With Asthma and Food Allergy · 2023 | This clinician | $2,325 |
| F. Hoffmann-La Roche AG · Safety Profile of Xolair in the Post Marketing Setting A Subanalysis of the Prospero Study · 2023 | This clinician | $1,161 |
| Novartis Pharma AG · Lou064 I Study · 2025 | This clinician | $54 |
| Novartis Pharma AG · Publication Support Research Related · 2020 | This clinician | $43 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225235120
- Licence
- CA A94106California A94106: Current · expires 2027-12-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0201X (207RA0201X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-07-02
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.